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Abstract
OBJECTIVES: Randomized controlled trials are the gold standard for evaluating health care interventions, yet are uncommon in children’s
heart surgery. We conducted a systematic review of clinical trials in paediatric cardiac surgery to evaluate the scope and quality of the cur-
rent international literature.
METHODS: We searched MEDLINE, CENTRAL and LILACS, and manually screened retrieved references and systematic reviews to identify
all randomized controlled trials reporting the effect of any intervention on the conduct or outcomes of heart surgery in children published
in any language since January 2000; secondary publications and those reporting inseparable adult data were excluded. Two reviewers
independently screened studies for eligibility and extracted data; the Cochrane Risk of Bias tool was used to assess for potential biases.
RESULTS: We identified 333 trials from 34 countries randomizing 23 902 children. Most were early phase (313, 94.0%), recruiting few
patients (median 45, interquartile range 28–82), and only 11 (3.3%) directly evaluated a surgical intervention. One hundred and nine
(32.7%) trials calculated a sample size, 52 (15.6%) reported a CONSORT diagram, 51 (15.3%) were publicly registered and 25 (7.5%) had a
Data Monitoring Committee. The overall risk of bias was low in 22 (6.6%), high in 69 (20.7%) and unclear in 242 (72.7%).
CONCLUSIONS: The recent literature in children’s heart surgery contains few late-phase clinical trials. Most trials did not conform to the
accepted standards of reporting, and the overall risk of bias was low in few studies. There is a need for high-quality, multicentre clinical tri-
als to provide a robust evidence base for contemporary paediatric cardiac surgical practice.
Keywords: Systematic review • Clinical trials • Paediatric cardiac surgery • Evidence-based medicine
INTRODUCTION
Congenital heart disease is the commonest type of congenital
anomaly, affecting 12 children born in the UK every day [1]. There
is a marked heterogeneity of structural cardiovascular defects,
often leading to cyanosis or heart failure and requiring complex
surgery in early childhood. Despite these challenges, advances in
paediatric cardiac surgery have been rapid, founded on the work
of visionary pioneers and improved incrementally through adjust-
ments in operative technique, supported by developments in
imaging, anaesthesia, intensive care, surgical technology and
hybrid approaches to management. Surgery is a high-tech, high-
stakes intervention that radically alters the natural history of con-
genital heart disease, especially for those at an early stage in their
life trajectory with the most to gain. Today, surgeons can offer the
prospect of ‘cure’ or successful palliation in almost all structural
congenital heart conditions, yet the impact of surgical techniques
and decision-making on long-term survival, reintervention, cardiac
function, exercise tolerance and quality of life is not fully under-
stood [2].
Randomized controlled trials (RCTs) represent the gold standard
in evaluating health care interventions through rigorous testing of
a predefined protocol with minimization of bias [3]. However,
much of modern paediatric cardiac surgical practice is based on
expert opinion, institutional case series or experimental evidence
derived from adults [4]. We therefore conducted a systematic
review of all RCTs assessing the outcomes of heart surgery in chil-
dren to identify the scope and quality of the current literature.
MATERIALS AND METHODS
This review was conducted with reference to the Cochrane
Handbook for Systematic Reviews [5, 6] and reported in accordance
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with the PRISMA statement [7], where appropriate. All eligibility cri-
teria, search terms and data items were prespecified.
Trial eligibility
All RCTs and quasi-RCTs reporting the effect of any intervention
on children undergoing cardiac surgery or their families published
in any language since 1 January 2000 were included. The definition
of a child was based on the authors’ characterization, and cardiac
surgery was defined as a therapeutic clinical procedure on the
heart or central vasculature, performed wholly or in part by a car-
diac surgeon, with or without the use of cardiopulmonary bypass.
Trials were excluded if the outcome measures were not directly
related to the conduct or outcomes of surgery, such as trials spe-
cifically and solely related to anaesthesia, analgesia, nutrition,
physiotherapy, pharmacokinetics, transplant immunosuppression
or weaning from ventilation. Invasive life support including extrac-
orporeal membrane oxygenation was excluded unless performed
as part of a primary cardiac surgical procedure. Trials including
both adults and children were only included if the publication pre-
sented the paediatric data separately. Secondary publications, sub-
studies and long-term outcomes of previously reported trials were
excluded, unless the results were specifically related to cardiac sur-
gery while the original was not. Trials published only as a confer-
ence abstract or for which all options to obtain the full text were
exhausted were excluded due to insufficient data.
Search strategy
We searched international primary research databases (PubMed,
CENTRAL and LILACS) from 1 January 2000 to 31 August 2016 and
reference lists of relevant articles and systematic reviews to identify
all eligible studies. We combined validated search strategies to
identify RCTs, studies including children and those involving cardiac
surgery (see Supplementary Material, Search Strategies). For exam-
ple, to identify the RCTs in PubMed, we used the Cochrane Highly
Sensitive Search Strategy for identifying randomized trials: sensitiv-
ity- and precision-maximizing version [5] and to identify studies
including children, we adapted the improved Cochrane Childhood
Cancer Group filter for PubMed developed by Leclercq et al. [8].
Study selection and data extraction
Abstracts and full-text publications of identified articles were
screened independently by two reviewers (N.E.D. and A.J.P.) to
generate a database of included studies. Data were extracted inde-
pendently by two reviewers (two of N.E.D., A.J.P. and N.K.O.) from
the full-text publication and any published protocols or supple-
mental material; assessments in previous systematic reviews were
corroborated. A full list of data items and definitions is available in
the Supplementary Material, Data items and definitions. Any dis-
crepancies were resolved by consensus. Non-English language
articles were evaluated in conjunction with individuals with a clini-
cal or research methodology background and fluent in that lan-
guage (C-RC for Chinese, see Acknowledgements for others).
Risk-of-bias assessment
The Cochrane Risk of Bias Tool was used to assess the methodo-
logical quality of eligible trials in 8 domains: sequence generation;
allocation concealment; blinding of participants, personnel and
outcome assessors; incomplete outcome data; selective outcome
reporting; and other potential threats to validity [6]. Trials were
rated as low, unclear or high risk of bias for each factor; the overall
risk of bias was determined for each trial as low (low risk in all
domains), high (high risk in one or more domains) or unclear (nei-
ther of the above).
Statistical analysis
Statistical analysis was performed using R (https://www.r-project.
org/). All continuous data were expressed as medians with inter-
quartile ranges (IQRs) and categorical data as counts and percen-
tages where relevant. The Fisher’s exact test was used to compare
categorical variables, and linear regression was used to model
the relationship between the number of children randomized per
trial and the year of publication. Significance testing was 2 sided
with the significance level determined at P < 0.05.
RESULTS
From 3158 unique records, we identified 333 RCTs published
since 1 January 2000, randomizing a total of 23 902 children
undergoing surgery. The flow of studies through the systematic
review process is documented in Fig. 1. All full-text articles were
sourced online, via national libraries or directly from the authors.
Characteristics of the included trials are listed in Table 1. The
majority of the studies were single-centre studies (318, 95.5%),
with only 7 (2.1%) trials conducted across more than 3 sites.
Trials originated from 34 countries (Fig. 2), with China (84,
25.2%), USA (65, 19.5%), India (21, 6.3%), Turkey (20, 6.0%) and
Japan (17, 5.1%) being the most frequent; only 5 (1.5%) trials
were multinational, conducted in 2 or 3 countries. Forty-three
(12.9%) trials were published in a language other than English: 35
(10.5%) in Chinese, 2 (0.6%) each in Korean and Turkish and 1
(0.3%) each in German, Persian, Portuguese and Russian. Trials
Figure 1: Study selection. *Retracted by the Editor. RCT: randomized controlled
trial.
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were most commonly published in specialist cardiothoracic sur-
gery journals (120, 36.0%), with few reaching high-impact cardio-
vascular [9, 2.7%: Circulation (5) and Journal of the American
College of Cardiology (4)] or general medical journals [6, 1.8%:
Lancet (3) and New England Journal of Medicine (3)]. The majority
of studies were Phase II (313, 94.0%), with only 15 (4.5%) Phase
III or IV trials; however, these late-phase trials were significantly
more likely to be published in high-impact journals (5/15 vs 10/
318, P = 0.0001).
In all trials, the subject of the intervention was the child under-
going surgery. The number of children randomized ranged
between 8 and 989 with a median of 45 patients (IQR 28–82);
17 (5.1%) trials analysed 100 or more patients per arm, with an
average of 1 trial per year worldwide. The number of children
randomized per trial by year is shown in Fig. 3; linear regression
showed a slight increase in the median number of patients per
trial over time (R2 0.026, P = 0.003). Recruitment rate was
reported in 59 (17.7%) articles, with a median of 90% (IQR 72–96)
of eligible children recruited, and trial duration was reported in
184 (55.3%), recruiting over a median of 18 (IQR 12–29) months.
Of those trials reporting a power calculation, 95 (87.2%) achieved
the target number of patients and 26 (7.8%) had a dropout rate
of 10% or more between randomization and analysis of the pri-
mary outcome.
The leading topics of investigation were cardiopulmonary
bypass techniques/components (92, 27.6%), myocardial protec-
tion strategies (60, 18.0%) and blood transfusion/conservation
methods (45, 13.5%). Drugs (171, 51.4%), cardiopulmonary
bypass techniques (78, 23.4%) and other techniques (43, 12.9%)
were the most frequently studied interventions (Table 2); com-
parison of 2 surgical approaches (6, 1.8%) or of a surgical techni-
que with an interventional catheter procedure (5, 1.5%) was less
commonly evaluated. A primary outcome measure was defined
in 193 (58.0%) trials and of these, 103 (53.4%) trials were clinical;
surrogate end-points only were reported in 144 (43.2%) trials.
Mortality was defined as an end-point in 12 (3.6%) studies, but
only 1 (0.3%) study demonstrated a survival difference between
groups [9].
Quality of trials
Regarding standards for the conduct and reporting of clinical tri-
als [3], 51 (15.3%) were prospectively registered on a publicly
accessible trial database, 109 (32.7%) performed a sample size
calculation, 25 (7.5%) were scrutinized by an independent Data
Monitoring Committee (DMC) and 52 (15.6%) published a
CONSORT flow diagram (Fig. 4). An explicit intention-to-treat
analysis was performed in 45 (13.5%) trials, a trial protocol pub-
lished in 9 (2.7%) and a Clinical Trials Unit or trial network
involved in 8 (2.4%). Nine (2.7%) trials were stopped early: 3 on
grounds of futility, 2 due to harm or side effects, 1 due to benefit
and 3 for logistical reasons (drug withdrawn or staff changes).
One (0.3%) trial was suspended by the DMC on safety grounds
Figure 2: World map of published trials by country of origin. Multinational trials are counted in each contributing country.
Table 1: Characteristics of the included trials
Characteristics n (%) Characteristics n (%)
Late phase (III or IV) 15 (4.5) Source of funding
Multinational 5 (1.5) Funding reported 138 (41.1)
Multicentre 15 (4.5) Publica 75 (22.5)
Continent of origin Institutionala 43 (12.9)
Asia 147 (44.1) Charity/privatea 30 (9.0)
Europea 92 (27.6) Commerciala 16 (4.8)
North Americaa 75 (22.5) None 16 (4.8)
Oceania 8 (2.4) Not reported 179 (53.8)
Africa 6 (1.8) Outcomes
South America 6 (1.8) Clinical 123 (36.9)
Language of
publication
Surrogate 144 (43.2)
English 290 (87.1) Combineda 66 (19.8)
Chinese 35 (10.5) Economica 1 (0.3)
Other 8 (2.4) Randomization
Design Simple unrestricted 87 (26.1)
Parallel groups 314 (94.3) Block/stratified 61 (18.3)
Factorial 16 (4.8) Minimization 5 (1.5)
Crossover 3 (0.9) Other technique 2 (0.6)
Number of arms Quasi- or non-randomb 17 (5.1)
2 279 (83.8) Unclear 161 (48.3)
3 41 (12.3) Explicit call for larger
trial to answer the
same question
89 (26.7)
4 or more 13 (3.9)
aIncludes multiple counting.
bSuch as allocation by alternation, hospital number or site.
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but restarted with an amended protocol and 2 (0.6%) were
extended, either by the DMC or by the regulator. Trials with
independent oversight were more likely to be stopped early or
suspended (4/25 vs 6/308, P = 0.004).
Risk-of-bias assessment for each of the 8 domains and overall
is shown in Fig. 5. The overall risk of bias was low for 22 (6.6%),
high for 69 (20.7%) and unclear for 242 (72.7%) trials; the high
proportion of unclear resulted from poor reporting of random-
ization and masking procedures and an inability to exclude selec-
tive reporting due to a lack of trial registration or published
protocol. All trials with a low risk of bias across all domains were
published since 2008 and were more likely to be Phase III, multi-
centre and conducted in Europe, North America or Australia (all
P < 0.005).
DISCUSSION
Randomized controlled trials only represent the gold standard
when appropriately designed, conducted and reported [3].
Although Phase II efficacy and safety trials have a role in deter-
mining whether potential treatments are worth pursuing, it is
Phase III clinical effectiveness trials that influence guidelines and
change practice. In this systematic review of the recent literature,
we identified 333 RCTs in children’s heart surgery from 34 coun-
tries reported since the turn of the millennium. These were
mostly single-centre, Phase II trials that were not prospectively
registered, recruited small numbers of patients without inde-
pendent oversight and were not reported to international stand-
ards [3, 10, 11]. Few studies dissected the merit of the surgical
interventions, instead focused on adjuncts such as cardiopulmo-
nary bypass or myocardial protection and examined surrogate
end-points that were susceptible to systematic bias. There was no
meaningful increase in the number of patients randomized per
trial over time, yet this did not appear to reflect difficulties in
recruitment: a median of 90% of eligible patients were recruited;
target sample size was achieved in 87% of studies and none was
stopped early due to poor recruitment.
Our findings are typical of the paediatric trials literature.
Hamm et al. [12] reported that only 12% of paediatric trials
declared prospective trial registration, fewer than 5% were over-
seen by a DMC and the risk of bias was low in 8% but high in
59% of trials. Similarly, Duffett et al. [13] found that half of paedi-
atric critical care trials randomized fewer than 50 patients, most
Figure 3: Logarithmic Tukey box plot of the number of children randomized per trial by year. Linear regression line (R2 0.026, P = 0.003) suggests no meaningful
change over time.
Table 2: Interventions studied
Interventions n (%) Interventions n (%)
CPB technique 78 (23.4) Drug 171 (51.4)
Ultrafiltrationa 22 (6.6) Protease inhibitor 25 (7.5)
Perfusiona 20 (6.0) Corticosteroidsa 23 (6.9)
Prime 18 (5.4) Cardioplegiaa 19 (5.7)
Temperaturea 8 (2.4) Pulmonary vasodilator 17 (5.1)
Reoxygenation 6 (1.8) Other vasoactive 15 (4.5)
Haemodilution 4 (1.2) Natural remedya 15 (4.5)
Other technique 43 (12.9) Anaesthetic agent 13 (3.9)
Ischaemic
conditioning
14 (4.2) Antiarrhythmic
Thyroid hormone
6 (1.8)
6 (1.8)
Surgical 6 (1.8) Recombinant factor 5 (1.5)
Surgery vs
interventional
5 (1.5) ACE inhibitor
Insulin
4 (1.2)
3 (0.9)
Drainage 4 (1.2) Other drug 20 (6.0)
Rewarming 4 (1.2) Blood/fluid
administration
20 (6.0)
Surgical access 3 (0.9)
Other technique 7 (2.1) Blood producta 17 (5.1)
Device 22 (6.6) Intravenous fluid 3 (0.9)
CPB circuita 13 (3.9) Miscellaneous 4 (1.2)
Haemostasis
management
4 (1.2) Music therapy
Other
2 (0.6)
2 (0.6)
Cell saver 2 (0.6)
Other device 3 (0.9)
aComparisons between interventions are counted in each category.
ACE: angiotensin-converting enzyme; CPB: cardiopulmonary bypass.
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Figure 4: Histograms of trial characteristics by year. (A) Published, by phase; (B) prospectively registered on a publicly accessible trial database; (C) reporting a sample
size calculation; (D) overseen by a Data Monitoring Committee (DMC) and (E) publishing a CONSORT flow diagram.
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focused on intermediate or surrogate outcomes, 43% reported a
target sample size, 15% were prospectively registered and the
overall risk of bias was low in only 4%. Furthermore, Shamliyan
and Kane [14] reported that of interventional studies involving
children registered on clinicaltrials.gov, only 29% of completed
studies were published in peer-reviewed journals, revealing a
substantial publication bias and implying that these may be just
the tip of a low-value, low-quality trial iceberg.
Contrary to adults with acquired disease, children with congeni-
tal heart disease present a range of complex anatomical and phys-
iological challenges that may require surgery at any stage of
development from preterm neonate to post-pubertal adolescent.
The immature heart, brain and other organs are often exposed to
chronic hypoxia prior to surgery, which may alter the ability to
cope with intraoperative or perioperative perturbations in blood
flow and oxygen delivery. Subsequent growth, or lack of it, may
significantly impact on the need for surgical or catheter reinterven-
tions, such as balloon dilatation, upsizing of conduits or
valve replacement. It is a founding principle of paediatrics that ‘chil-
dren are not just small adults’, yet many aspects of current practice
have been extrapolated from adult studies, using ‘hand-me-down’
paradigms with little or no paediatric data to support their applica-
tion [15–18]. Surgical trials in children are considered more chal-
lenging due to a number of factors including: few cases per centre,
resulting from the low disease burden and heterogeneity of condi-
tions; complex procedures with marked variations in practice
between surgeons and institutions; low mortality rates yet a lack of
other validated clinical outcome measures; greater scrutiny from
ethics committees and regulators; the higher cost of paediatric tri-
als; and a perceived lack of willingness of surgeons and parents to
enter their children into randomized trials [4, 19]. These barriers
predispose to inadequate power leading to inconclusive results,
increased uncertainty and ineffective use of resources.
To address these concerns, the Paediatric Heart Network
(PHN) was established in 2001 by the National Heart, Lung and
Blood Institute, using an investigator-led model of core clinical
centres and auxiliary sites across the USA and Canada [4, 17].
Policies and procedures are developed by a Central Steering
Committee, with representation from all participating centres,
and implemented by a Data Coordinating Centre, with scientific
and safety oversight provided by Protocol Review Committee
and DMC, respectively. This explicit engagement of clinical inves-
tigators coupled with central investment in personnel and infra-
structure have been fundamental to their success. The landmark
Single Ventricle Reconstruction (SVR) trial randomized 555
infants with single-ventricle lesions (84% of those eligible) to the
Norwood procedure, with either a modified Blalock–Taussig
shunt or a right ventricle to pulmonary artery shunt across 15
sites in just over 3 years [9]. This trial demonstrated not only the
power of collaboration to increase sample size in a rare condition
but also that surgeons and parents were willing to randomize
children to different treatments, even in high-risk complex neo-
natal cardiac surgery, when there is clinical equipoise [17]. To
date, it has produced more than 20 publications including a pub-
licly available data set and remains the only Phase III trial in
children’s heart surgery to demonstrate a difference in 1-year
transplant-free survival [9]; perhaps, more importantly, this differ-
ence was lost by 3 years [20], and further follow-up is keenly
awaited. Unfortunately, despite being uniquely positioned to
conduct such trials, the SVR trial remains the only surgical inter-
ventional trial of the PHN to be completed, and no similar stud-
ies are currently recruiting [21].
Of the trials identified in this review, 10 (3.0%) were conducted
in the UK. All were single-centre Phase II trials, randomizing 431
patients in total, or less than 1% of the approximately 65 000
children who underwent cardiac surgery in the National Health
Service (NHS) over the same period [22]. In contrast, more than
70% of children diagnosed with cancer in the UK are currently
enrolled into national or international Phase III clinical trials [23];
this approach has played a key role in the dramatic increase in
Figure 5: Risk of bias.
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survival of childhood cancers over the past 50 years, and provid-
ing the opportunity to participate in such a trial is now consid-
ered best practice [24]. With national commissioning of specialist
services and cradle-to-grave follow-up, plus access to National
Institute of Health Research infrastructure and well-developed
Clinical Trials Units, the modern NHS should be an ideal environ-
ment to conduct multicentre RCTs in children’s heart surgery.
However, in the wake of the Bristol Royal Infirmary Inquiry of
2001 [25], the focus of UK paediatric cardiac surgical centres was
on maintaining and improving standards of direct patient care;
research has been a secondary consideration and has since
lagged behind other specialities. The new Congenital Heart
Disease review of services in England intends to centralize clinical
care into fewer, larger Specialist Children’s Surgical Centres
within regional networks and deems participation in research to
be an essential activity [26]. Indeed, 2 recent multicentre observa-
tional studies, the Infant Heart Study and the Cardiac Morbidity
Study [27, 28], have demonstrated an appetite for collaboration
in the UK, and both congenital heart disease and cardiovascular
surgery have been identified by the British Heart Foundation as
key elements of their research funding strategy [1].
The outcomes of cardiac surgery in children have improved
markedly over the recent decades [2], yet continued improve-
ment will require a team science approach with robust, multi-
centre, Phase III clinical trials central to providing the evidence
base for clinical practice. There remain many important unan-
swered questions, such as surgical valvotomy versus balloon val-
vuloplasty for aortic stenosis or comparing types of right
ventricle to pulmonary artery conduit, and these are better
addressed by late-phase trials rather than endless cycles of pro–
con expert debates. A solution to the lack of such trials both in
the UK and elsewhere is the development of specific national
congenital heart disease research networks, following a similar
model to the PHN, with the potential for large-scale international
collaborations. The SVR trial has set the standard for the evalua-
tion of surgical interventions in congenital heart disease [4, 9];
this review suggests that in the design, conduct and reporting of
future trials, we should:
• Identify key research questions of genuine clinical equipoise
that are of the greatest importance to all stakeholders includ-
ing children, parents, clinicians, researchers, charities, funders
and industry.
• Obtain preliminary data from observational studies, disease-
specific registries and nationally reported data sets to assess
feasibility and identify potential outcome measures [4, 28].
• Select a validated, standardized, clinically important primary
end-point as part of a minimum core outcome set for congen-
ital heart disease to facilitate meta-analyses of pooled data [29].
• Ensure an adequate sample size and timely recruitment
through an inclusive, collaborative approach to multicentred
trials with investment from local investigators and patient
organizations through all stages of the trial.
• Identify a priori subgroups that may show differential
responses to interventions, such as neonates or those with
chronic hypoxaemia, ensuring sufficient power to avoid Type
II errors [16].
• Utilize existing Clinical Trial Units and Clinical Research
Network infrastructure to facilitate efficient multisite set-up
and delivery.
• Conduct and report the trial rigorously to international stand-
ards [3, 11, 30], minimizing potential biases and upholding the
quality of data and outputs.
• Provide oversight by an independent DMC to ensure the
safety of participants and the integrity of trial data [16].
• Facilitate ancillary studies and public data sharing to maximize
the value of trial investment [4].
• Engage and educate the wider community through user
involvement and understand their perspectives on research
involving children to improve the design and conduct of trials.
Strengths and limitations
The strengths of this systematic review include the comprehen-
sive search strategy, independent review procedures and obtain-
ment of the full text of all potential articles in all languages. The
limitations include a risk of reporting bias, although unpublished
studies would be expected to be less well conducted, and limiting
the scope to RCTs, which are not the only source of valuable evi-
dence to inform clinical practice.
CONCLUSION
‘Lack of research, poor research, and poorly reported research
are violations of children’s human rights’—Richard Horton, ple-
nary address to 1st StaR Child Health summit 2009 [11].
In conclusion, this systematic review demonstrates that the
recent literature in paediatric cardiac surgery contains few late-
phase clinical trials. Most published trials are small, single-centre
studies of low value and uncertain quality, providing a limited
evidence base for contemporary practice. As a congenital heart
disease community, we have the responsibility to provide scien-
tific leadership and work together to conduct well-designed, rig-
orously conducted, multicentre clinical trials with clearly defined,
clinically relevant end-points that answer important questions to
improve the outcomes of surgery for our patients and their fami-
lies. Our colleagues in other specialties, such as paediatric oncol-
ogy [23], have made the opportunity to participate in late-phase
clinical trials part of the routine care pathway and so must we—
carpe diem.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
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